[{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Timber Pharmaceuticals"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"U.S. Food & Drug Administration ","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"$0.5 million","newsHeadline":"Timber Pharmaceuticals Announces Award of Second Tranche of FDA Orphan Products Clinical Trials Grant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ U.S. Food & Drug Administration ","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ U.S. Food & Drug Administration "},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals Announces Merger Closing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pharmaceuticals \/ BioPharmX"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces All CONTROL Study Sites Open and Enrolling Patients with Moderate to Severe Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech\u2019s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Douglas CDMO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Isotretinoin Capsules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Douglas Pharmaceuticals Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Douglas Pharmaceuticals Ltd"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Mayne Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Three Additional Strengths Of Isotretinoin Capsules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Mayne Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Mayne Pharma"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Isotretinoin Capsules, USP","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"$14.0 million","newsHeadline":"LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ LEO Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ LEO Pharma"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEO Pharma Finalizes Acquisition of Key Assets from Timber Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ LEO Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ LEO Pharma"}]
Find Clinical Drug Pipeline Developments & Deals for Accutane
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
